Fennell DA - Search Results

1

Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Klabatsa A, et al. Among authors: fennell da. Lung Cancer. 2006 Jan;51(1):53-9. doi: 10.1016/j.lungcan.2005.07.010. Epub 2005 Sep 16. Lung Cancer. 2006. PMID: 16169121

2

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

Fennell DA, Rudd RM. Fennell DA, et al. Lancet Oncol. 2004 Jun;5(6):354-62. doi: 10.1016/S1470-2045(04)01492-5. Lancet Oncol. 2004. PMID: 15172356 Review.

3

Pulmonary toxicity and cancer treatment.

Fennell DA, Rudd RM. Fennell DA, et al. Hosp Med. 2004 Aug;65(8):462-5. doi: 10.12968/hosp.2004.65.8.15490. Hosp Med. 2004. PMID: 15330346 Review.

4

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Fennell DA, et al. J Clin Oncol. 2005 Jan 1;23(1):184-9. doi: 10.1200/JCO.2005.07.050. J Clin Oncol. 2005. PMID: 15625372

5

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Fennell DA, et al. Lung Cancer. 2005 Feb;47(2):277-81. doi: 10.1016/j.lungcan.2004.08.005. Lung Cancer. 2005. PMID: 15639727 Clinical Trial.

6

Prognostic factors in mesothelioma.

Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Steele JP, et al. Among authors: fennell da. Lung Cancer. 2005 Jul;49 Suppl 1:S49-52. doi: 10.1016/j.lungcan.2005.03.009. Lung Cancer. 2005. PMID: 15894403

7

Molecular and Immunological approaches.

Fennell DA. Fennell DA. Lung Cancer. 2005 Jul;49 Suppl 1:S87. doi: 10.1016/j.lungcan.2005.03.016. Epub 2005 Apr 22. Lung Cancer. 2005. PMID: 15950808 No abstract available.

8

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. Szlosarek PW, et al. Among authors: fennell da. Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101. Clin Cancer Res. 2006. PMID: 17145837

9

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

10

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

Fennell DA, Steele JP, Shamash J, Slater SE, Sheaff MT, Wells P, Rudd RM, Stebbing J. Fennell DA, et al. Int J Cancer. 2007 Dec 1;121(11):2575-7. doi: 10.1002/ijc.22984. Int J Cancer. 2007. PMID: 17680556 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page